Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

Choose the language:

  Homepage
Continue on the current website:  

 

Alt tag

aBSI

  • Extraprostatic lesions
  • Bone Scintigraphy

aBSI provides detection and quantification of lesions for evaluation of Prostate Cancer Progression. EXINI Automated Bone Index (aBSI) marks the lesions and quantifies the disease burden.

aBSI

Images shown for illustrative purposes only.

Circle

Improve inter-observer agreement with Automated BSI interpretation (k=0.96) versus qualitative visual assessment (k=0.70)1

Circle

aBSI has an independent association with overall survival (HR, 1.06; 95% CI, 1.01-1.11; P = 0.03)1

Clinical Workflow

clearread workflow

For CalanticTM software version 1.0.0 and older versions, no prior study will be examined.

white bg

 

    Appropriate Series

    Number of frames (0028,0008) must be 1 or 2

    Number of slices (0054,0081) must be 1 or 2

    Pixel spacing (0028,0030) must be ≥ 1.8 mm/pixel and ≤ 2.8 mm/pixel

    The anterior and posterior images may be stored as either two different series (two files with different Series Instance UID) or as one multi-frame series (one file) containing two frames.

    Image pixel data should be in the 16-bit range. Images with pixels ranging from 0 to 255 (8- bit) are not sufficient.

    Picture Archiving and Communications System (PACS) tool, clinical application for oncology, including lesion marking and quantitative analysis (Calculation of Bone Scan Index (BSI)).

      Currently not made available with Calantic Viewer. Separately distributed by Bayer.

       

      EU risk class and CE marking
      aBSI has CE marking (CE0123) and risk class IIa.

      Reimbursement status
      Not reimbursed.

      Contraindications
      No contraindications given.

      Target population
      Not indicated.

      Intended user
      Trained healthcare professionals and researchers.

      Limitations
      BSI should not be reported:

      - for patients with non-metastatic prostate cancer (M0),

      - if image input requirements are not fulfilled,

      - if atlas does not match the imaged skeleton,

      - if the image(s) contains a large hotspot that includes the urinary bladder

        1.
        Instructions for Use aBSI, software version 3.6
        App gallery wave image
        Discover ClearRead CT

        Discover aBSI

        now available as part of Calantic’s Prostate Service Line. Contact us today to learn more.

        Get a Demo

        Other Offerings in the Prostate Service Line

        Exini logo
        Prostate

        aPROMISE

        • Prostatic lesions
        • PET/CT
        • Extraprostatic lesions
        Quantib
        Prostate

        Quantib Prostate

        • Intraprostatic lesions
        • MRI